Eli Lilly and Company, Merck & Co., Inc., AbbVie, Gilead Sciences, and Insmed are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Error: Response status code does not indicate success: 429 (Too Many Requests). These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
NYSE:LLY traded up $19.82 during mid-day trading on Friday, reaching $879.55. The stock had a trading volume of 1,828,113 shares, compared to its average volume of 3,429,713. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. The stock has a market capitalization of $833.96 billion, a PE ratio of 75.07, a P/E/G ratio of 1.40 and a beta of 0.51. Eli Lilly and Company has a 12 month low of $677.09 and a 12 month high of $972.53. The stock has a 50-day simple moving average of $827.14 and a two-hundred day simple moving average of $818.81.
Read Our Latest Research Report on LLY
Merck & Co., Inc. (MRK)
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.
Merck & Co., Inc. stock traded up $2.82 during mid-day trading on Friday, hitting $82.66. 18,491,324 shares of the stock were exchanged, compared to its average volume of 11,859,363. The company has a quick ratio of 1.15, a current ratio of 1.36 and a debt-to-equity ratio of 0.79. The stock has a market capitalization of $208.44 billion, a price-to-earnings ratio of 12.25, a PEG ratio of 0.77 and a beta of 0.40. The firm's fifty day simple moving average is $87.06 and its two-hundred day simple moving average is $95.41. Merck & Co., Inc. has a 12 month low of $75.93 and a 12 month high of $134.63.
Read Our Latest Research Report on MRK
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
NYSE:ABBV traded up $6.65 on Friday, hitting $187.02. The stock had a trading volume of 6,597,689 shares, compared to its average volume of 6,048,173. AbbVie has a 52 week low of $153.58 and a 52 week high of $218.66. The business's fifty day moving average is $197.05 and its 200 day moving average is $187.28. The company has a quick ratio of 0.55, a current ratio of 0.66 and a debt-to-equity ratio of 17.94. The company has a market cap of $330.83 billion, a PE ratio of 77.85, a P/E/G ratio of 1.62 and a beta of 0.55.
Read Our Latest Research Report on ABBV
Gilead Sciences (GILD)
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Shares of NASDAQ GILD traded down $2.77 during trading on Friday, hitting $103.38. The stock had a trading volume of 8,350,038 shares, compared to its average volume of 7,534,886. Gilead Sciences has a 12 month low of $62.07 and a 12 month high of $119.96. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The firm has a fifty day moving average of $109.26 and a two-hundred day moving average of $98.03. The company has a market capitalization of $128.73 billion, a PE ratio of 279.99, a PEG ratio of 0.71 and a beta of 0.32.
Read Our Latest Research Report on GILD
Insmed (INSM)
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.
Insmed stock traded up $0.39 during trading on Friday, hitting $69.35. The stock had a trading volume of 11,922,826 shares, compared to its average volume of 2,291,767. The stock has a market cap of $12.61 billion, a price-to-earnings ratio of -12.40 and a beta of 1.07. The stock's 50 day moving average is $74.61 and its two-hundred day moving average is $73.55. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. Insmed has a 1 year low of $21.92 and a 1 year high of $84.91.
Read Our Latest Research Report on INSM
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
